ITIH1

ITIH1 encodes heavy chain H1 of the inter-alpha-trypsin inhibitor (ITI) complex, a liver-expressed secreted glycoprotein that is assembled with heavy chain H2 and bikunin via a chondroitin sulfate cross-link and functions primarily in extracellular matrix organization through covalent transfer to hyaluronan (PMID:2476436, PMID:7592891). The C-terminal Asp of ITIH1 is esterified to an internal N-acetylglucosamine of hyaluronan chains, a transfer catalyzed by TSG-6, which also liberates free bikunin as an active serine protease inhibitor; pentraxin 3 (PTX3) binds the ITI heavy chains to cooperatively organize hyaluronan matrices essential for processes such as cumulus oophorus expansion (PMID:7592891, PMID:16873769, PMID:17675295). As a secreted protein, ITIH1 also acts as an integrin α5β1 ligand that competes with fibronectin to suppress FAK signaling, and its expression is negatively regulated both epigenetically by KDM5C-mediated H3K4me1 demethylation and post-transcriptionally by TGF-β-driven METTL3 m6A modification, with loss of ITIH1 activating NF-κB and PI3K/AKT pathways to promote hepatocellular and renal cell carcinoma progression (PMID:39234824, PMID:35080113, PMID:39091412).

1. 1987 High

   Resolving the long-standing question of whether ITI is a single polypeptide or a multi-component complex, cDNA cloning demonstrated that ITIH1 is a distinct heavy chain encoded by its own mRNA and expressed exclusively in liver, establishing the multi-gene architecture of the ITI system.

   Evidence cDNA cloning, RNA blot, cell-free translation, partial amino acid sequencing from two independent groups

   PMID:2446322 PMID:3663330

   Open questions at the time

   • No functional assay for isolated H1 chain
   • Post-translational assembly mechanism unknown
2. 1989 High

   The molecular basis of ITI assembly was established: H1 and H2 are joined to bikunin not by peptide bonds but via a glycosaminoglycan (chondroitin sulfate) cross-link, explaining the unusual multi-chain architecture and sensitivity to hyaluronidase/chemical deglycosylation.

   Evidence SDS-PAGE, trifluoromethanesulfonic acid treatment, hyaluronidase digestion of purified plasma ITI

   PMID:2476436

   Open questions at the time

   • Precise chemical nature of the glycan–protein bond not yet resolved
   • Assembly pathway in hepatocytes unknown
3. 1993 High

   The extracellular function of ITIH1 was reframed when its gene product was identified as the serum-derived hyaluronan-associated protein (SHAP), demonstrating that HC1 is covalently transferred from ITI to hyaluronan chains, with the HA-binding determinant mapped to the C-terminal half of the protein.

   Evidence Protein sequencing of HA-lyase-released peptides, Western blot with anti-ITI antibodies, in vitro incubation of serum with exogenous HA

   PMID:7504674

   Open questions at the time

   • Enzyme or catalyst mediating the transfer not identified
   • Structural basis of C-terminal HA binding unresolved
4. 1995 High

   The atomic-level linkage chemistry was defined: the C-terminal Asp of HC1/ITIH1 forms an ester bond to the C6-hydroxyl of an internal GlcNAc residue in the hyaluronan chain, providing the precise covalent mechanism for HA cross-linking.

   Evidence ESI-MS/MS and CID-MS/MS of thermolysin-digested SHAP·HA complex from human synovial fluid

   PMID:7592891

   Open questions at the time

   • Transferase catalyzing the ester bond formation not yet identified
   • Reversibility and turnover of the linkage unknown
5. 2006 High

   TSG-6 was identified as the catalyst that forms covalent intermediates with ITI heavy chains including HC1, driving their transfer to HA and simultaneously releasing free bikunin as an active serine protease inhibitor, connecting ITIH1 metabolism to airway antiprotease defense.

   Evidence Immunoprecipitation from bronchoalveolar lavage fluid, in vitro reconstitution with purified TSG-6/ITI, primary human airway epithelial cells with TNF-α/IL-1β stimulation

   PMID:16873769

   Open questions at the time

   • Catalytic mechanism of TSG-6 in transesterification not structurally resolved
   • Whether TSG-6 is the sole catalyst in all tissues unknown
6. 2007 High

   PTX3 was shown to directly bind ITI heavy chains (including HC1) through its N-terminal domain, and this interaction is required for organizing hyaluronan matrices in the cumulus oophorus, as demonstrated by rescue of the Ptx3-knockout matrix-assembly defect and blockade by an anti-PTX3 antibody.

   Evidence Co-IP from cumulus matrix, solid-phase binding with purified proteins, PTX3 domain mapping, Ptx3−/− cumulus culture rescue, blocking antibody

   PMID:17675295

   Open questions at the time

   • Stoichiometry of the PTX3–HC1 complex on HA not determined
   • Whether PTX3 interaction is required for HA stabilization beyond cumulus matrix unknown
7. 2022 Medium

   Epigenetic regulation of ITIH1 was established: KDM5C silences ITIH1 transcription by demethylating H3K4me1 at its promoter in HCC cells, and double-knockdown epistasis showed that ITIH1 loss downstream of KDM5C reactivates PI3K/AKT signaling and restores malignant behavior.

   Evidence siRNA KD of KDM5C, ChIP for H3K4me1 at ITIH1 promoter, KDM5C/ITIH1 double KD epistasis, xenograft tumor model

   PMID:35080113

   Open questions at the time

   • Whether KDM5C is recruited to ITIH1 promoter by a specific transcription factor is unknown
   • Single-lab finding; independent replication needed
   • Direct protein-level readout of ITIH1 secretion after KDM5C manipulation not shown
8. 2024 High

   ITIH1 was shown to function as a secreted integrin α5β1 ligand that competes with fibronectin to suppress FAK signaling in HCC, while TGF-β promotes METTL3 phase separation to m6A-modify ITIH1 mRNA and reduce its stability, providing a unified post-transcriptional and signaling mechanism for ITIH1 tumor suppression.

   Evidence Co-IP/binding assays for ITIH1–integrin α5β1, fibronectin competition, FAK phosphorylation, m6A-seq/MeRIP, METTL3 phase-separation imaging, in vivo HCC model, patient-derived organoids and xenografts, recombinant ITIH1 treatment

   PMID:39234824

   Open questions at the time

   • Structural basis of ITIH1–integrin α5β1 binding versus the established HA-ester function not reconciled
   • Whether integrin antagonism is independent of HA binding unknown
9. 2024 Medium

   ITIH1 was independently shown to suppress RCC progression via negative regulation of NF-κB signaling, with pharmacological rescue by the NF-κB inhibitor JSH-23 confirming pathway epistasis.

   Evidence siRNA KD and overexpression in RCC cell lines, Western blot for NF-κB pathway, proliferation/invasion assays, JSH-23 pharmacological rescue

   PMID:39091412

   Open questions at the time

   • Mechanism by which a secreted protein inhibits intracellular NF-κB not defined
   • No in vivo model provided
   • Relationship between NF-κB suppression and integrin/FAK pathway unclear

• Key unresolved questions include the structural basis for ITIH1's dual roles in HA cross-linking and integrin antagonism, how secreted ITIH1 accesses intracellular NF-κB signaling, and whether the tumor-suppressive function operates through the same C-terminal domain responsible for HA esterification.
• No high-resolution structure of ITIH1 or ITIH1–HA complex
• No genetic loss-of-function animal model for ITIH1
• Relationship between HA stabilization and tumor-suppressive signaling unexplored